Page 153 - Eceptor News Today

MARTINSRIED (dpa-AFX) - BioNTech SE (BNTX) and Medigene AG (MDGEF.PK) said that they have reached a multi-target research collaboration to develop T cell receptor or TCR based immunotherapies against

Researchers attempted to delineate the duration and stability of anti-SARS-CoV-2 antibodies in patients who had recovered from the COVID-19 infection.

Researchers demonstrated the potent neutralization of SARS-CoV-2 VOCs, including Omicron by the biparatopic human heavy chain variable domain.

BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer •Collaboration leverages... | February 22, 2022

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping HIV antiretroviral drug treatment, suggesting a cure, according to the Weill Cornell Medicine physician-scientists who performed the transplant and managed her care

Researchers have developed a new vaccine candidate that is specifically targeted against the SARS-CoV-2 Omicron variant.

A new study explains how SARS-CoV-2 adapts its immunogenicity to the immune response of the host.

A new Virology study shows that the N-glycosylation pattern of SARS-CoV-2 is crucial to normal spike activity.

A recent study identified six candidate mutations in the SARS-CoV-2 genome adaptive to animal hosts.

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.